India is a big market for healthcare, said Sushil Suri, chairman of Morepen Laboratories, on Wednesday. Suri also said that currently, the company has 5 abbreviated new drug applications (ANDAs) in the pipeline.
Switzerland-based Corinth Group to invest USD 100 million in the Morepen Group with USD 32.5 million going towards a 9.41 percent stake in Morepen Laboratories.
Speaking in an interview with CNBC-TV18, Suri said, “Healthcare is our main focus and India is a big market for healthcare and we have already announced an expansion plan of active pharmaceutical ingredient (API) and then we have expansion coming up on ANDAs. We have 5 ANDAs for the US market.”
“At this AGM we are going to put up the dividend policy also because in the last 20 years the company has not paid a single dividend,” said Suri.
For the entire management interview, watch the video